Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Andros Pharmaceuticals Co's Enterprise Value is NT$1,553.50 Mil.
Andros Pharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-46.44 Mil. Therefore, Andros Pharmaceuticals Co's EV-to-FCF for today is -33.46.
The historical rank and industry rank for Andros Pharmaceuticals Co's EV-to-FCF or its related term are showing as below:
ROCO:6917'
s EV-to-FCF Range Over the Past 10 Years
Min: -30.68 Med: -8.91 Max: -3.57
Current: -28.63
During the past 7 years, the highest EV-to-FCF of Andros Pharmaceuticals Co was -3.57. The lowest was -30.68. And the median was -8.91.
ROCO:6917's EV-to-FCF is ranked worse than 100% of 335
companies
in the Biotechnology industry
Industry Median: 15.51
vs ROCO:6917: -28.63
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Andros Pharmaceuticals Co (ROCO:6917) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Andros Pharmaceuticals Co's PE Ratio (TTM) for today is calculated as:
Andros Pharmaceuticals Co's share price for today is NT$34.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Andros Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.160.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Andros Pharmaceuticals Co EV-to-FCF Related Terms
Andros Pharmaceuticals Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6917 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Andros Pharmaceuticals Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Andros Pharmaceuticals Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Andros Pharmaceuticals Co's EV-to-FCF falls into.
Andros Pharmaceuticals Co's current Enterprise Value is NT$1,553.50 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Andros Pharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-46.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Andros Pharmaceuticals Co (ROCO:6917) has a EV-to-FCF of -33.46 as of Jul. 17, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Andros Pharmaceuticals Co and its competitors. According to the industry distribution chart, Andros Pharmaceuticals Co ranks #999999 out of 335 companies in the Biotechnology industry.
Is Andros Pharmaceuticals Co's EV-to-FCF too high?
Andros Pharmaceuticals Co's current EV-to-FCF is -33.46. Based on the distribution chart, Andros Pharmaceuticals Co ranks #999999 out of 335 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Andros Pharmaceuticals Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Andros Pharmaceuticals Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Andros Pharmaceuticals Co ranks #999999 out of 335 companies for EV-to-FCF. This places Andros Pharmaceuticals Co in the lower half of its industry. The industry median EV-to-FCF is 15.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.51, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Andros Pharmaceuticals Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Andros Pharmaceuticals Co's current EV-to-FCF is -33.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Andros Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co (ROCO:6917) is currently considered Possible Value Trap. The stock's GF Value™ is NT$165.02, compared to a current price of NT$34.50 — trading 79.1% below its estimated fair value. The current EV-to-FCF is -33.46. Andros Pharmaceuticals Co's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Andros Pharmaceuticals Co (ROCO:6917), the current EV-to-FCF is -33.46 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$34.50 is trading 79.1% below its estimated GF Value™ of NT$165.02.
GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for ROCO:6917:
EV-to-FCF: -33.46
GF Value™: NT$165.02 vs. price of NT$34.50 (79.1% below fair value)
No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
41GF Score
Get the complete analysis for ROCO:6917
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6917 has been successfully added to your 
